274results about "Fermentation" patented technology

The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

This invention provides methods for massive parallel nucleic acid analysis. A closed complex of nucleic acid template, nucleotide and polymerase can be formed during polymerase reaction, absent divalent metal ion. This is used to trap the nucleotide complementary to the next template nucleotide in the closed complex. Detection of the trapped nucleotide allows determination of the sequence of this next correct nucleotide. In this way, sequential nucleotides of a nucleic acid template can be identified, effectively determining the sequence. This method is applied to sequence multiple templates in parallel, particularly if they are immobilized on a solid support.

A method of modifying the content of certain chemical compounds in tobacco materials is provided, the method including treatment of a tobacco plant component with at least one probiotic. For example, the method may modify the asparagine content in tobacco materials, which can result in a modification in acrylamide production when the tobacco material is exposed to elevated temperatures. The type of tobacco plant component treated according to the invention can be a tobacco seed, a tobacco seedling, an immature live plant, a mature live plant, a harvested plant, or a portion thereof. Examples of probiotics include probiotic species of the genera bifidobacterium, lactobacillus, enterococcus, proionobacterium, bacillus, saccharomyces, streptococcus, and mixtures thereof. Smoking articles and other tobacco products including such probiotic-treated tobacco materials are also provided.

Disclosed is a process for extracting xylose and xylitol from a xylose mother liquor or a xylose digest, which comprises, using xylose hydrolysate or xylose mother liquid as the raw material, removing glucose through saccharomyces cerevisiae fermentation, then imitating moving bed, using water as eluent, completely separating xylose from foreign matter such as arabinose, thus obtaining component containing rich xylose.

The process for the treatment of ligno-cellulosic biomass comprises the steps of:

• • A) Soaking a ligno-cellulosic biomass feedstock in vapor or liquid water or mixture thereof in the temperature range of 100 to 210° C. for 1 minute to 24 hours to create a soaked biomass containing a dry content and a first liquid;
  • B) Separating at least a portion of the first liquid from the soaked biomass to create a first liquid stream and a first solid stream; wherein the first solid stream comprises the soaked biomass; and
  • C) Steam exploding the first solid stream to create a steam exploded stream comprising solids and a second liquid.

According to the invention, there is provided seed and plants of the corn variety designated CV252827. The invention thus relates to the plants, seeds and tissue cultures of the variety CV252827, and to methods for producing a corn plant produced by crossing a corn plant of variety CV252827 with itself or with another corn plant, such as a plant of another variety. The invention further relates to corn seeds and plants produced by crossing plants of variety CV252827 with plants of another variety, such as another inbred line. The invention further relates to the inbred and hybrid genetic complements of plants of variety CV252827.

The invention relates to a method for manufacturing a recombinant polyclonal protein composition, in particular a recombinant polyclonal antibody composition. The method comprises obtaining a collection of cells transfected with a library of variant nucleic acid sequences, wherein each cell in the collection is transfected with and capable of expressing one member of the library, which encodes a distinct member of a polyclonal protein that binds a particular antigen and which is located at the same single site in the genome of individual cells in said collection, wherein said nucleic acid sequence is not naturally associated with said cell in the collection. The cells are cultured under suitable conditions for expression of the polyclonal protein, which is obtained from the cells or culture supernatant. The nucleic acid sequence id introduced into the cells by transfection with a library of vectors for site-specific integration. The present method is suitable for manufacturing recombinant polyclonal antibodies, thereby mailing available a superior replacement of plasma-derived therapeutic immunoglobulin products.

The invention provides a method of RNA interference, which comprises contacting the cell with a fusion protein-double stranded RNA complex, the complex comprising the double stranded RNA segment containing a double stranded RNA of interest and a fusion protein, the fusion protein comprising (1) a targeting moiety, which will specifically binds to a site on a target cell, and (2) a binding moiety, which will bind to the double stranded RNA, wherein the double stranded RNA segment initiates RNA interference in the cell.

The invention provides an amphiphilic copolymer comprising monomer units derived from a first monomer and monomer units derived from a second monomer. The copolymer has at least one hydrophobic endgroup. The first monomer is such that the copolymer is thermally responsive and the second monomer comprises a carboxylic acid or carboxylate group.

A fermentation process for the production of ethanol from natural sources, such as corn, comprising introducing a fermentable sugar and an inoculant, and a bacteriophage cocktail into a fermentation system and introducing a cocktail comprising one or more lytic bacteriophage is added to one or more of the fermentable sugar, the inoculant, or the fermentation system. Bacteriophages that infect and lyse the bacteria that contaminate fermentable sugars are selected. The bacteriophage cocktail is added in an amount effective to substantially prevent growth of these bacteria.

The invention discloses a production method of L-phosphinothricin. According to the method, 2-carbonyl-4-(hydroxymethylphosphonyl)butyric acid is used as a substrate and is catalyzed by an enzyme catalytic system to obtain L-phosphinothricin, and the enzyme catalytic system is composed of gamma-aminobutyric acid/alpha-ketoglutarate transaminase, glutamate dehydrogenase and a coenzyme regeneration system. The method utilizes the advantages of high catalytic activity, strong stereoselectivity and the like of transaminase, and also solves the problem of incomplete transaminase catalytic reaction, so that the catalytic reaction can completely convert the substrate 2-carbonyl-4-(hydroxymethylphosphonyl)butyric acid into L-phosphinothricin, and the conversion rate can reach 100%; no by-product alpha-ketoglutarate is accumulated in the final product of the method, and the residual amount of other substances such as the raw material glutamic acid in the product after the end of the reaction is extremely low, so the subsequent refining process of L-phosphinothricin is greatly simplified, and the total yield of the product is increased.

The present invention provides, in part, methods for recombinantly expressing proteins at a high level along with cell culture media for doing the same.

Described herein are methods of inhibiting M-CSF activity, and, in particular, M-CSF/c-fms dependent cell signaling. In a first embodiment of the invention, one administers to a mammal viral vectors that deliver genes experessing antisense c-fms RNA; in a second embodiment, one induces in vivo production of a high-affinity soluble c-fms protein that competes for non-bound M-CSF; in a third embodiment, one administers a ribozyme-viral vector against c-fms mRNA; and in a fourth embodiment, one administers oligodeoxynucleotides that inhibit expression of c-fms gene product. The methods may be used to treat any disease in which M-CSF activity plays a role, and are particularly effective in treating and preventing atherosclerosis.

Embodiments of the present invention are directed primarily, but not exclusively, to a method for treating and preventing cardiovascular disease by inhibiting receptors to M-CSF. Other embodiments of the present invention include any and all biologic and/or pathobiologic phenomena mediated in whole or in part by M-CSF signaling through its receptor. Pathobiologic phenomena include, but are not limited to, disease entities such as osteoporosis, Alzheimer's disease, diabetes mellitus (Type 1 and/or Type 2), infectious diseases, cancer, and inherited disorders characterized by defects in one or more components in the M-CSF signaling pathway.

A method for detecting human papillomaviruses (HPV) in biological material is described, in which method nucleic acids are extracted/isolated from biological material and HPV-specific DNA is detected in the isolated nucleic acids. This method uses at least one of the nucleotide sequences SEQ ID No. 1 or SEQ ID No. 2 from the enclosed sequence listing or sequences which bind to sequences to which one of the sequences SEQ ID No. 1 or SEQ ID No. 2 binds or sequences which are complementary to the abovementioned sequences.

The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.

A process for extracting heparin sodium from pig lungs and co-producing polypeptide protein powder. Two products of heparin sodium and polypeptide protein powder can be obtained at the same time with one feeding. It includes the following steps: (1) raw material pretreatment; (2) enzymatic hydrolysis; (3) salt hydrolysis twice; (4) slag (protein) removal and clear liquid collection; (5) ultrafiltration and concentration to remove ash; (6) Ammonium salt precipitation; (7) precipitation of heparin sodium, and vacuum drying to obtain crude heparin sodium; (8) enzymatic precipitation; (9) decolorization; (10) pressure filtration; (11) spray drying. The process is co-production, which has a higher utilization rate of equipment than a single production process, saves raw materials, auxiliary materials, and manpower, and can reduce the production cost of heparin sodium and polypeptide protein powder; make full use of my country's pig lung resources to increase the added value of pig lung; reduce protein-containing waste Liquid waste slag pollutes the environment, and turning waste into treasure is an effective way to supplement the shortage of protein feed resources in our country.

The invention discloses a method for producing astaxanthin by inducing Haematococcus pluvialis, which is characterized by comprising the following steps: in the vegetative growth phase, inoculating Haematococcus pluvialis in a nutrient culture medium, and culturing; continuously keeping irradiation on the Haematococcus pluvialis and ensuring that the intensity of illumination arriving at the Haematococcus pluvialis cell surface is 20-200 mu mol.m<-2>.s<-1>; in the induction stage, adding ethanol and seawater crystal into the production culture medium, wherein the ethanol added into the production culture medium accounts for 0.5-3 vol%, and the seawater crystal added into the production culture medium accounts for 0.5-1 wt%; and continuously introducing filtered air mixed with 1-3 vol% carbon dioxide into the production culture medium, wherein 0.2-0.4L/minute of the air is introduced to every 1L of production culture medium. The method can induce the Haematococcus pluvialis to quickly accumulate the astaxanthin, is simple and has the advantages of high yield and favorable effect.

The present invention provides an improved method for gene delivery in eukaryotic cells by electroporation, preferably in human hematopoietic cells, particular dendritic cells. The method of the invention is superior to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for gene delivery, including tumor antigen loading of dendritic cells.

The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as an anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred imbodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals.

The invention discloses preparation of organic solvent slow release system and its application in enzyme catalysis reaction. It is formed by multi-hole solid matter and liquid state organic matter. The saturated solid matter reacts with vegetable oil under immobilization lipase and solvent at 30 centigrade degree for 12hr. Its product biological diesel oil yield can reach above 90%. Meanwhile the reclaimed immobilization lipase still holds high catalysis energy.

A membrane supported bioreactor arrangement and method for anaerobic conversion of gas into liquid products including membrane modules having hollow fibers packed across a cross sectional area of the membrane module, each of the hollow fibers formed from an asymmetric membrane wall having a porous outer layer defining biopores for retaining a porous biolayer about the outer surface of the membrane wall and a less permeable hydration layer around the hollow fiber lumen; a membrane vessel for surrounding the outside of the hollow fibers with a process gas from a gas supply conduit; and a liquid supply conduit operably connected to the hollow fibers for supplying a process liquid to the hollow fiber lumens. The gas supply conduit enables the formation of a biolayer on the outer surface of the hollow fiber wall by interaction of microorganisms with the process gas and the production of a liquid product.

The invention relates to a processing method of changing food waste into resources. Ethanol, methane, liquid fertilizers, solid fertilizers, pet food and the like can be obtained through the following steps of food waste solid and liquid separation and respectively treatment after the food, the potato type, the vegetable melon and fruit type, the animal meal and fish bone type and rubbish sundries are sorted from the solid, and oil for producing biodiesel, soap and glycerin, purified water used for fish culture, water plant planting and farmland and garden irrigation and the like can be obtained after liquid treatment. The methane is used for combustion after being dewatered, and is used for electric power generation after being desulfurized, and the waste heat of the electric power generation is reused. The method of the invention fully utilizes waste materials, produces various products, and has the advantages of low energy consumption and high yield.